Details for New Drug Application (NDA): 211280
✉ Email this page to a colleague
The generic ingredient in REYVOW is lasmiditan succinate. One supplier is listed for this compound. Additional details are available on the lasmiditan succinate profile page.
Summary for 211280
Tradename: | REYVOW |
Applicant: | Eli Lilly And Co |
Ingredient: | lasmiditan succinate |
Patents: | 2 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 211280
Generic Entry Date for 211280*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 211280
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
REYVOW | lasmiditan succinate | TABLET;ORAL | 211280 | NDA | Eli Lilly and Company | 0002-4312 | 0002-4312-08 | 2 BLISTER PACK in 1 CARTON (0002-4312-08) / 4 TABLET in 1 BLISTER PACK |
REYVOW | lasmiditan succinate | TABLET;ORAL | 211280 | NDA | Eli Lilly and Company | 0002-4312 | 0002-4312-61 | 1 BLISTER PACK in 1 CARTON (0002-4312-61) / 4 TABLET in 1 BLISTER PACK |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 50MG BASE | ||||
Approval Date: | Jan 31, 2020 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Jan 31, 2025 | ||||||||
Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Dec 5, 2037 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patented Use: | ACUTE TREATMENT OF MIGRAINE | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 17, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patented Use: | ACUTE TREATMENT OF MIGRAINE |
Expired US Patents for NDA 211280
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | ⤷ Sign Up | ⤷ Sign Up |
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | ⤷ Sign Up | ⤷ Sign Up |
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription